BioSante Pharmaceuticals, Inc. Announces Receipt of National Institutes of Health (NIH) Grant for Inhaled Interferon

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that the company has been awarded a $150,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the company's development of formulations for the pulmonary delivery of interferon alpha (IFN-a) using its proprietary calcium phosphate nanoparticulate (CaP) technology.